MDM2 and acute myeloid leukemia: The study concluded that AML cells with normal karyotype and wild-type status of TP53 with elevated FLT3 and MDM2 expression are most sensitive to the combined treatment with cobimetinib and idasanutlin (Seipel et al., 2018).